This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bone Metabolism Therapeutics Market To 2018 - Hyperparathyroidism Sector To Decline In The Absence Of New Product Launches And Increased Generic Erosion For Zemplar, Hectorol And Sensipar

- Key M&A activities and Licensing Agreements that took place in 2009 and 2011 in the metabolic disorders therapeutics market.


Reasons to buy


- Align your product portfolio to the markets with high growth potential.

- Build effective strategies to launch their pipeline products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.




Table of Contents

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 9

2 Introduction 11

3 Bone Metabolism Therapeutics Market to 2018 - Market Overview 12

3.1 Introduction 12

3.1.1 Revenue 12

3.1.2 Annual Cost of Treatment 13

3.1.3 Treatment Usage Patterns 14

4 Bone Metabolism Therapeutics Market to 2018 - Geographical Landscape 16

4.1 Revenue Analysis by Geography 16

4.2 The US 18

4.2.1 Revenue 18

4.2.2 Annual Cost of Treatment 19

4.2.3 Treatment Usage Patterns 20

4.3 Top Five Countries of Europe 22

4.3.1 Revenue 22

4.3.2 Annual Cost of Treatment 24

4.3.3 Treatment Usage Patterns 25

4.4 Japan 27

4.4.1 Revenue 27

4.4.2 Annual Cost of Treatment 28

4.4.3 Treatment Usage Patterns 29

5 Bone Metabolism Therapeutics Market to 2018 - Therapeutic Landscape 31

5.1 Osteoporosis Therapeutics Market 31

5.1.1 Introduction 31

5.1.2 Revenue 31

5.1.3 Annual Cost of Treatment 35

3 of 10

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs